Pediatric Liver Tumors: Types, Symptoms, and Treatment

Liver tumors in children are uncommon, accounting for roughly one to two percent of all pediatric cancers, but they span a wide range of types with very different outlooks.¹ About two-thirds of childhood liver tumors turn out to be malignant, while the rest are benign growths that often resolve on their own or need only monitoring.² The specific type of tumor, the child’s age at diagnosis, and whether the mass has spread all shape what treatment looks like and how well it works.

Malignant Pediatric Liver Tumors

Hepatoblastoma

Hepatoblastoma is far and away the most common liver cancer in children, typically appearing before age three. It originates from immature liver cells and is strongly associated with certain genetic conditions. Children with Beckwith-Wiedemann syndrome, for instance, carry germline changes on chromosome 11p15 that, combined with later tumor-specific mutations, can drive the cancer forward.³ Familial adenomatous polyposis (FAP), caused by mutations in the APC gene, also raises hepatoblastoma risk. Very low birth weight and prematurity are additional recognized risk factors, though most cases arise in otherwise healthy children with no known predisposition.

One of the hallmarks of hepatoblastoma is a markedly elevated blood level of alpha-fetoprotein (AFP). Nearly all hepatoblastomas produce AFP, and tracking its rise and fall becomes central to monitoring treatment response, as discussed later in this article.⁴

Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the second most common malignant liver tumor in children, but it behaves quite differently from hepatoblastoma. It tends to appear in older children and teenagers, and unlike hepatoblastoma, it often arises against a backdrop of pre-existing liver disease. The main risk factors in childhood include chronic hepatitis B infection and a set of inherited metabolic disorders such as hereditary tyrosinemia, glycogen storage diseases, familial progressive intrahepatic cholestasis, and Alagille syndrome.⁵ HCC in children is generally harder to treat than hepatoblastoma, partly because it responds less reliably to chemotherapy and partly because it tends to be diagnosed at a more advanced stage. A distinct subtype called fibrolamellar HCC sometimes appears in adolescents without underlying liver disease and carries its own prognosis.

Embryonal Sarcoma of the Liver

Undifferentiated embryonal sarcoma of the liver (UESL) is the third most common malignant liver tumor in children, though it is still rare. It mostly affects children under fifteen and arises from the liver’s connective tissue rather than from liver cells themselves.⁶ UESL can be tricky to diagnose because on imaging it sometimes looks like a fluid-filled cyst rather than a solid tumor. Its relationship with mesenchymal hamartoma, a benign liver growth in young children, is one of the more interesting threads in pediatric liver oncology. Both share chromosomal changes at the same location (19q13), and there is evidence that some embryonal sarcomas develop from a pre-existing mesenchymal hamartoma.⁷ These tumors tend to be large at diagnosis, often exceeding ten centimeters, and treatment usually involves surgery combined with chemotherapy.⁸

Benign Liver Tumors

Infantile Hepatic Hemangiomas

Hemangiomas are the most common benign liver tumors in infants. They are vascular growths that follow a distinctive natural course: a phase of rapid growth during the first year of life, followed by a period of gradual shrinkage that can last months or years.⁹ Many small, solitary hemangiomas cause no symptoms and need only observation. When they grow large enough to press on surrounding structures, trap blood platelets (a complication called Kasabach-Merritt phenomenon), or shunt enough blood to stress the heart, treatment becomes necessary. Propranolol, a beta-blocker originally developed for heart conditions, has become a first-line medical therapy for symptomatic infantile hemangiomas. Not all hepatic hemangiomas are the same biologically, though. The ones classified as infantile hemangiomas express a marker called GLUT-1 and tend to respond to propranolol, while congenital hemangiomas, which are present in their full size at birth, do not express GLUT-1 and typically do not respond to the drug.¹⁰

Mesenchymal Hamartoma

Mesenchymal hamartoma of the liver usually presents in children under two as a painless, sometimes enormous abdominal mass. It is technically a developmental anomaly rather than a true tumor, made up of a primitive stromal tissue with fluid-filled cystic spaces lined by bile duct-like structures. Underlying genetic changes on chromosome 19q13 are a recurrent cause.¹¹ These growths are benign, but their sheer size can cause symptoms by compressing the stomach or diaphragm, and surgical removal is the standard approach. The link between mesenchymal hamartoma and embryonal sarcoma, mentioned above, is reason enough for clinicians to follow up after resection, even though malignant transformation is uncommon.

Focal Nodular Hyperplasia and Hepatic Adenoma

Focal nodular hyperplasia (FNH) and hepatic adenoma are benign liver masses more commonly discussed in adults, but they do occur in children. FNH is essentially an overgrowth of normal liver tissue around an abnormal blood vessel, and it almost never causes complications or requires treatment. Hepatic adenoma is rarer in children and carries a small risk of bleeding or, very rarely, malignant change. Telling the two apart on imaging matters because their management differs. Contrast-enhanced ultrasound, already well established in adult practice, shows good reliability for distinguishing FNH from adenoma in children as well.¹²

How Pediatric Liver Tumors Present

The most common first sign of a liver tumor in a child is an abdominal mass, usually noticed by a parent during bathing or dressing, or by a pediatrician during a routine exam. The mass is typically painless in the early stages. Depending on the tumor’s size and location, a child may have abdominal swelling, decreased appetite, weight loss, or vague discomfort. Jaundice is surprisingly uncommon. Standard liver function tests, including markers of bile flow and liver cell damage, are often normal even when a malignant tumor is present.⁴ That mismatch between a large mass and reassuringly normal blood work can sometimes delay diagnosis.

For malignant tumors, the picture at presentation is frequently advanced. In one series, roughly seventy percent of children with malignant primary liver tumors had disseminated disease at the time of their initial evaluation.⁴ The lungs are the most common site for spread. This underscores why any unexplained abdominal mass in a young child warrants prompt imaging rather than watchful waiting.

Diagnosis and the Role of AFP

Once a liver mass is found on ultrasound, cross-sectional imaging with CT or MRI is used to define its extent. A blood test for AFP is one of the most informative early steps. In hepatoblastoma, AFP is elevated in the overwhelming majority of cases, sometimes to extraordinarily high levels. AFP is also elevated in most pediatric HCC, though a minority of both tumors can be AFP-negative.⁴ It is worth knowing that healthy newborns have naturally high AFP levels that decline over the first year of life, so interpreting AFP in very young infants requires age-adjusted reference ranges.

AFP is not just a diagnostic marker. It acts as a real-time gauge of how a tumor is responding to treatment. A rapid drop in AFP after chemotherapy, specifically a decline of at least two logarithmic units before the second surgery, has been shown to be one of the strongest predictors of a good outcome in hepatoblastoma.¹³ Conversely, sluggish AFP decline after the first cycle of chemotherapy or persistently high AFP before surgery signals a worse prognosis.¹⁴ After surgery, the speed at which AFP falls to normal provides another clue: when AFP drops with a half-life of about four days, it is consistent with complete tumor removal. A much longer half-life suggests residual disease still producing AFP somewhere.¹⁵

Staging With PRETEXT

Malignant pediatric liver tumors are staged using a system called PRETEXT (PRE-Treatment EXTent of tumor), originally developed in the early 1990s by the International Childhood Liver Tumor Strategy Group (SIOPEL) and since adopted by cooperative groups worldwide.¹⁶ PRETEXT divides the liver into four sections and assigns a group (I through IV) based on how many sections contain tumor. Alongside that basic grouping, a set of annotation factors records whether the tumor involves the portal vein, hepatic veins, or inferior vena cava, whether there is extrahepatic spread, multifocality, tumor rupture, or lung metastases.¹⁷ Together, the PRETEXT group and annotations form the backbone of risk stratification, guiding decisions about whether a child needs chemotherapy before surgery, how aggressive that chemotherapy should be, and whether liver transplantation might be necessary.

Biopsy is sometimes needed to confirm the diagnosis, especially when imaging and AFP are not conclusive. For hepatoblastoma, percutaneous needle biopsy under image guidance is generally safe. The theoretical risk of seeding tumor cells along the needle track, a genuine concern in adult HCC, has proven to be exceedingly rare in hepatoblastoma, particularly when the needle passes through a layer of normal liver tissue.¹⁸

Treatment of Hepatoblastoma

Treatment for hepatoblastoma is built around two pillars: surgery to remove the tumor and chemotherapy to shrink it and eliminate microscopic disease. The modern approach stratifies patients into risk groups based on PRETEXT staging, tumor biology, AFP levels, the presence of metastases, and how well the tumor responds to initial chemotherapy.¹⁹

For children whose tumors are small and clearly resectable at diagnosis (generally PRETEXT I or II), upfront surgery is the recommended first step. A successful removal can be as limited as taking out a single liver segment or section, as long as the margins are free of tumor. In some of these lower-risk cases, the child may need only a short course of chemotherapy afterward, or in selected very-low-risk cases, chemotherapy can potentially be avoided entirely.²⁰ A trial by the Children’s Oncology Group showed that children with hepatoblastoma resected at diagnosis could be safely treated with as little as two cycles of cisplatin-based chemotherapy, reducing exposure to drugs that cause hearing damage.²¹

When the tumor is too large or involves too many liver sections to remove safely at diagnosis, treatment starts with chemotherapy to shrink it. Cisplatin is the backbone drug. Standard-risk and low-risk patients are often treated with cisplatin alone or combined with 5-fluorouracil and vincristine. High-risk patients, such as those with metastatic disease or tumors involving major vessels, need more intensive regimens adding drugs like doxorubicin and carboplatin.¹⁹

Age sometimes raises concern in the operating room. Surgeons can be cautious about performing extensive liver resections in infants. However, comparative data from centers performing major resections, including trisectionectomies, show that infants tolerate these operations about as well as older children, suggesting that aggressive surgery should not be withheld solely because of young age.²²

When the Tumor Cannot Be Removed by Standard Surgery

Some hepatoblastomas involve all four liver sections (PRETEXT IV) or sit in locations that make conventional resection impossible even after chemotherapy. In these cases, liver transplantation becomes the curative option. Transplantation for hepatoblastoma yields strong results: one study found five-year survival of about ninety percent after transplant, comparable to the ninety-six percent seen after standard liver resection, with no recurrences in the transplant group over that period.²³ The decision to pursue transplant requires careful coordination, because chemotherapy must control the disease long enough for an organ to become available.

Bridging therapies that keep the tumor in check while a child awaits transplant are an active area of interest. One approach gaining attention is transarterial radioembolization with yttrium-90 (Y90), in which tiny radioactive beads are delivered through a catheter directly into the blood vessels feeding the tumor. Case reports and small series in children show that Y90 can control tumor size and drive down AFP levels, buying time for transplant or sometimes making a tumor resectable when it previously was not.²⁴ Early experience suggests the procedure is technically feasible even in toddlers and can be repeated if needed.²⁵

Immunotherapy and GPC3-Targeted Approaches

Researchers are looking beyond conventional chemotherapy for new ways to treat pediatric liver cancers. One particularly promising target is glypican-3 (GPC3), a protein found on the surface of hepatoblastoma and HCC cells but largely absent from normal tissue. In a pediatric phase I trial in Japan, a GPC3-directed vaccine was found to be safe, with roughly two-thirds of patients showing disease control at two months. An immune response against GPC3 was detected in about forty percent of participants, most of whom were hepatoblastoma patients in remission.²⁶ Building on those results, trials of engineered T cells (CAR-T cells) directed against GPC3 have been developed for both adults with HCC and children with GPC3-positive liver tumors. These are still early-stage, but the concept of training the immune system to recognize and destroy liver cancer cells specifically is one of the more exciting frontiers in pediatric oncology.

Long-Term Health After Treatment

Surviving a pediatric liver tumor is only part of the story. The treatments themselves, particularly chemotherapy and radiation, can leave lasting marks on the liver and other organs. In a large cohort of long-term childhood cancer survivors, about nine percent had signs of liver damage detected by abnormal blood enzyme levels years after treatment ended.²⁷ Risk factors for these late liver effects included radiation to the liver, higher body mass index, greater alcohol intake, and longer time since treatment.²⁸

Radiation deserves special mention. Although radiation therapy is not a standard part of hepatoblastoma treatment, children treated for other cancers sometimes receive radiation that incidentally involves the liver. A modeling study found that the risk of a specific complication called sinusoidal obstruction syndrome rises with increasing radiation dose to the liver and is amplified when certain chemotherapy drugs are given alongside.²⁹ Reassuringly, rates of severe late liver injury after radiation for common childhood cancers appear low overall.

Beyond the liver, cisplatin, the workhorse drug in hepatoblastoma treatment, is known to cause hearing loss, particularly at the higher frequencies that matter for speech comprehension. This is part of what motivates the push to reduce chemotherapy exposure in lower-risk patients. Kidney function, heart health (when doxorubicin has been used), and general growth and development all warrant long-term follow-up. Most pediatric cancer centers run dedicated survivorship clinics to screen for these effects and intervene early.

How Age Shapes the Tumor Landscape

A child’s age at diagnosis is one of the strongest clues to what type of tumor is present. The youngest infants, under six months, are most likely to have hepatic hemangiomas or, less commonly, hepatoblastoma. Between six months and three years, hepatoblastoma dominates the malignant category, while mesenchymal hamartoma is the leading benign possibility. Older children and adolescents are the age group where HCC, embryonal sarcoma, and FNH appear. This age-linked pattern helps clinicians narrow down what they are dealing with even before biopsy results come back.³⁰ Age also influences treatment tolerance and prognosis in ways that are still being studied. Very young infants with hepatoblastoma tend to present with lower-stage disease and, in many cases, more favorable biology, though the counterweight is that delivering chemotherapy and performing surgery on a baby who weighs a few kilograms demands specialized expertise.

1
PubMed. Benign and Malignant Pediatric Liver Masses: Radiologic-Pathologic Update from the Pediatric LI-RADS Working Group
2
Clinics and Research in Hepatology and Gastroenterology. Hepatic neoplasms in children: A focus on differential diagnosis
3
PubMed Central. Genomic profiles of a hepatoblastoma from a patient with Beckwith-Wiedemann syndrome with uniparental disomy on chromosome 11p15 and germline mutation of APC and PALB2
4
PubMed. Pediatric liver tumors: initial presentation, image finding and outcome
5
Journal of Exploratory Research in Pharmacology. Pediatric Hepatocellular Carcinoma: Metabolic Causes and Possible Prevention
6
PubMed Central. Undifferentiated Embryonal Sarcoma of the Liver in Pediatrics: A Diagnostic Challenge With Implications for Early Management
7
PubMed Central. Hepatic mesenchymal hamartoma and undifferentiated embryonal sarcoma of the liver: a pathologic review
8
PubMed Central. Embryonal sarcoma of the liver in pediatric and young adult patients: A report from Children’s Oncology Group study ARST0332
9
PubMed Central. Efficacy of infantile hepatic hemangioma with propranolol treatment
10
Pediatr Gastroenterol Hepatol Nutr. Treatment of Symptomatic Focal Hepatic Hemangioma with Propranolol in Neonates: Is It Efficient?
11
PubMed. Mesenchymal Hamartoma of the Liver and DICER1 Syndrome
12
PubMed. Contrast-enhanced ultrasound in the diagnosis of pediatric focal nodular hyperplasia and hepatic adenoma: interobserver reliability
13
PubMed. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome
14
PubMed. Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma
15
PubMed. Actual half-life of alpha-fetoprotein as a prognostic tool in pediatric malignant tumors
16
PubMed Central. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group
17
PubMed. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT)
18
PubMed Central. Evaluation of Diagnostic Biopsy Approach for Children with Hepatoblastoma: A Report from the Children’s Oncology Group AHEP 0731 Liver Tumor Committee
19
Clin Pediatr Hematol Oncol. Management of Hepatoblastoma in the Modern Era and Future Perspectives – Section: Multicenter Clinical Trials and Current Treatment Guidelines
20
Seminars in Pediatric Surgery. Critical elements of pediatric liver cancer surgery – Section: 1. Conventional resection of pediatric liver tumors at diagnosis
21
The Lancet Oncology. Risk-adapted therapy for low-risk hepatoblastoma
22
Journal of Pediatric Surgery. Surgical outcomes of liver resection for hepatoblastoma in infants versus older children: A bi-centric, propensity-score-matched, comparative study
23
PubMed Central. Liver Transplantation Is Highly Effective in Children with Irresectable Hepatoblastoma
24
PubMed Central. Yttrium-90 Transarterial Radioembolization as a Bridging Therapy to Liver Transplant in a Toddler With Pretreatment Extent (PRETEXT) IV Hepatoblastoma
25
PubMed. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children
26
Frontiers in Oncology. Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors – Section: Treatments
27
European Journal of Cancer. Surveillance of hepatic late adverse effects in a large cohort of long-term survivors of childhood cancer: Prevalence and risk factors
28
PubMed Central. Hepatic late adverse effects after antineoplastic treatment for childhood cancer
29
International Journal of Radiation Oncology*Biology*Physics. Liver Late Effects in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review
30
PubMed Central. Pediatric Primary Hepatic Tumors: Diagnostic Considerations